
Abiomed ABMD
Quarterly report 2022-Q3
added 11-03-2022
Abiomed General and Administrative Expenses 2011-2026 | ABMD
General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.What these expenses include
- Salaries of administrative staff (executives, HR, accountants, legal personnel)
- Office rent and utilities
- Office equipment and IT infrastructure
- Professional services (auditors, lawyers, consultants)
- Insurance
- General administrative travel and representation expenses
- Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure - Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit - Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry - Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines
Annual General and Administrative Expenses Abiomed
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 334 M | 342 M | 322 M | 263 M | 218 M | 164 M | 126 M | 107 M | 84.2 M | 71.7 M | 62.3 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 342 M | 62.3 M | 190 M |
Quarterly General and Administrative Expenses Abiomed
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 117 M | 235 M | - | 108 M | 103 M | 206 M | - | 86.2 M | 86.2 M | 79.2 M | 68.4 M | 85.7 M | 85.7 M | 86 M | 86.1 M | 80.2 M | 80.2 M | 78.9 M | - | 66.6 M | 60.1 M | 60.6 M | - | 53.9 M | 158 M | 104 M | - | 41.9 M | 119 M | 77.2 M | - | 30.1 M | 91.2 M | 29.5 M | - | 24.4 M | 78.5 M | 54.2 M | - | 20.9 M | 60.3 M | 39.4 M | - | 17.2 M | 51.7 M | 34.5 M | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 235 M | 17.2 M | 79.6 M |
General and Administrative Expenses of other stocks in the Medical devices industry
| Issuer | General and Administrative Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
BIOLASE
BIOL
|
10.2 M | - | -13.19 % | $ 166 K | ||
|
GenMark Diagnostics, Inc.
GNMK
|
25.6 M | - | - | $ 1.77 B | ||
|
Allied Healthcare Products
AHPI
|
7.11 M | - | 3.58 % | $ 2.21 M | ||
|
Eargo
EAR
|
54.3 M | - | - | $ 10.2 M | ||
|
Helius Medical Technologies
HSDT
|
9.27 M | $ 2.18 | 0.93 % | $ 1.33 M | ||
|
Apollo Endosurgery
APEN
|
20.6 M | - | - | $ 475 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
8.78 M | - | -5.86 % | $ 30.6 M | ||
|
Delcath Systems
DCTH
|
43.5 M | $ 11.09 | 0.64 % | $ 397 M | ||
|
Second Sight Medical Products
EYES
|
1.11 M | - | -0.97 % | $ 54.4 M | ||
|
Electromed
ELMD
|
39.3 M | $ 25.56 | -0.23 % | $ 216 M | ||
|
Avinger
AVGR
|
14.1 M | - | -20.74 % | $ 369 K | ||
|
Axonics Modulation Technologies
AXNX
|
40.2 M | - | - | $ 3.31 B | ||
|
EDAP TMS S.A.
EDAP
|
5.9 M | $ 3.49 | 4.49 % | $ 131 M | ||
|
Aziyo Biologics
AZYO
|
15.1 M | - | 1.37 % | $ 20.5 M | ||
|
BioSig Technologies
BSGM
|
67.5 M | - | 37.08 % | $ 85.7 M | ||
|
Conformis
CFMS
|
28.8 M | - | - | $ 16.4 M | ||
|
Inspire Medical Systems
INSP
|
625 M | $ 46.07 | -16.05 % | $ 1.35 B | ||
|
ClearPoint Neuro
CLPT
|
16.5 M | $ 11.01 | -1.52 % | $ 312 M | ||
|
LivaNova PLC
LIVN
|
549 M | $ 58.97 | -0.18 % | $ 3.22 B | ||
|
Cardiovascular Systems
CSII
|
171 M | - | 0.15 % | $ 844 M | ||
|
Cytosorbents Corporation
CTSO
|
35.6 M | $ 0.62 | -0.02 % | $ 38.6 M | ||
|
CryoLife, Inc.
CRY
|
141 M | - | -4.14 % | $ 702 M | ||
|
Invacare Corporation
IVC
|
227 M | - | - | $ 24.7 M | ||
|
Soliton, Inc.
SOLY
|
8.46 M | - | -1.42 % | $ 435 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
4.88 K | - | -1.98 % | $ 98.3 M | ||
|
IRIDEX Corporation
IRIX
|
7.73 M | $ 1.06 | -2.3 % | $ 18 M | ||
|
Itamar Medical Ltd.
ITMR
|
8.5 M | - | 0.03 % | $ 1.58 B | ||
|
Dynatronics Corporation
DYNT
|
8.46 M | - | 14.99 % | $ 929 K | ||
|
Misonix, Inc.
MSON
|
18 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
14.7 M | - | - | $ 111 M | ||
|
OrthoPediatrics Corp.
KIDS
|
120 M | $ 15.78 | - | $ 370 M | ||
|
Sintx Technologies
SINT
|
6.2 M | $ 2.38 | -1.65 % | $ 6.6 M | ||
|
Butterfly Network
BFLY
|
39.8 M | $ 4.97 | 2.58 % | $ 1.05 B | ||
|
Intersect ENT, Inc.
XENT
|
98.6 M | - | - | $ 955 M | ||
|
GBS
GBS
|
8.88 M | - | -0.57 % | $ 7.12 M | ||
|
Globus Medical
GMED
|
1.18 B | $ 90.18 | -0.46 % | $ 12.2 B | ||
|
NanoVibronix
NAOV
|
7.63 M | - | - | $ 1.08 M | ||
|
CONMED Corporation
CNMD
|
132 M | $ 36.28 | 1.03 % | $ 1.13 B | ||
|
Integer Holdings Corporation
ITGR
|
212 M | $ 83.51 | -0.6 % | $ 2.9 B | ||
|
TransMedics Group
TMDX
|
185 M | $ 96.22 | -0.89 % | $ 3.27 B | ||
|
Stryker Corporation
SYK
|
8.65 B | $ 291.43 | 0.2 % | $ 111 B | ||
|
Tandem Diabetes Care
TNDM
|
445 M | $ 19.16 | -3.59 % | $ 1.3 B | ||
|
Edwards Lifesciences Corporation
EW
|
2.09 B | $ 82.17 | -1.4 % | $ 48.1 B | ||
|
LENSAR
LNSR
|
45.2 M | $ 5.51 | -0.9 % | $ 65.9 M | ||
|
Pulmonx Corporation
LUNG
|
101 M | $ 1.32 | -0.75 % | $ 53.7 M | ||
|
MiMedx Group
MDXG
|
56.5 M | $ 3.65 | 1.11 % | $ 539 M | ||
|
Myomo
MYO
|
14 M | $ 0.86 | - | $ 36 M | ||
|
Cutera
CUTR
|
63.3 M | - | -10.19 % | $ 1.99 M |